Oculis Holding Ag Revenue Growth Rates (OCS), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Oculis Holding Ag  (NASDAQ: OCS)
 

OCS's Revenue Growth by Quarter and Year

Oculis Holding Ag's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

OCS Revenue (in millions $) FY 2025 FY 2024 FY 2023 FY 2022
4th Quarter December 1.45
3rd Quarter September 0.00
2nd Quarter June 0.00
1st Quarter March 0.00
FY 1.45





OCS Revenue fourth quarter 2025 Y/Y Growth Comment
Oculis Holding Ag achieved in the fourth quarter 2025, above Company average Revenue rise of 85.55% year on year, to $ 1.45 millions.

Looking into fourth quarter 2025 results within Major Pharmaceutical Preparations industry 86 other companies have achieved higher Revenue growth. While Oculis Holding Ag' s Revenue jump of 85.55% ranks overall at the positon no. 1922 in the fourth quarter 2025.


OCS Revenue ( Y/Y Growth %) 2025
 2024 2023 2022
4th Quarter December 85.55 % -20.41 % 2.08 % -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY   85.55 % -20.41 % 2.08 % -

Financial Statements
Oculis Holding Ag's fourth quarter 2025 Revenue $ 1.45 millions OCS's Income Statement
Oculis Holding Ag's fourth quarter 2024 Revenue $ 0.78 millions Quarterly OCS's Income Statement


OCS Revenue (Quarter on Quarter Growth %)

 2025
 2024 2023 2022
4th Quarter December - - - -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY (Year on Year)   85.55 % -20.41 % 2.08 % -


Back to OCS Growth rate Comparisons >> Back to OCS Growth rate Comparisons >>


Revenue fourth quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #87
Healthcare Sector #259
Overall #1922

Revenue Y/Y Growth Statistics
High Average Low
-3.18 % -3.18 % -3.18 %
(Dec 31 2023)  
Revenue fourth quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #87
Healthcare Sector #259
Overall #1922
Revenue Y/Y Growth Statistics
High Average Low
-3.18 % -3.18 % -3.18 %
(Dec 31 2023)  

Revenue by Quarter for the Fiscal Years 2022, 2023, 2024, 2025

Oculis Holding Ag's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


OCS's IV. Quarter Q/Q Revenue Comment


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


OCS's IV. Quarter Q/Q Revenue Comment


Oculis Holding Ag's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Dec 31 2024)		 12 Months Ending
(Dec 31 2023)		 12 Months Ending
 12 Months Ending
Cumulative Revenue 12 Months Ending $ 1.20 $ 0.69 $ 0.88 $ 0.00 $ 0.00
Y / Y Revenue Growth (TTM) 74.78 % -22.31 % -3.18 % - -
Year on Year Revenue Growth Overall Ranking # 1922 # 2588 # 2530 # 0 # 0
Seqeuential Revenue Change (TTM) 74.78 % -22.31 % -3.18 % - -
Seq. Revenue Growth (TTM) Overall Ranking # 1922 # 2588 # 2530 # 0 # 0


Cumulative Revenue growth Comment
Oculis Holding Ag saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 74.78% year on year, to $ 1 millions if the fiscal year would have ended in Dec 31 2025.
Oculis Holding Ag's trailing twelve months Revenue growth was higher than company's average -3.18% and higher than -22.31% growth in Dec 31 2024.
The momentum is even more impressive from twelve months ended Dec 31 2024 exhibited at 74.78 % increase from $0.69 millions in the period from Dec 31 2024 to .

In the Healthcare sector 258 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 1922, from total ranking in previous quarter at 2588.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 87
Healthcare Sector # 259
Overall # 1922

Revenue TTM Y/Y Growth Statistics
High Average Low
-3.18 %
 -3.18 %
-3.18 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 87
Sector # 259
S&P 500 # 1922
Cumulative Revenue growth Comment
Oculis Holding Ag saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 74.78% year on year, to $ 1 millions if the fiscal year would have ended in Dec 31 2025.
Oculis Holding Ag's trailing twelve months Revenue growth was higher than company's average -3.18% and higher than -22.31% growth in Dec 31 2024.
The momentum is even more impressive from twelve months ended Dec 31 2024 exhibited at 74.78 % increase from $0.69 millions in the period from Dec 31 2024 to .

In the Healthcare sector 258 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 1922, from total ranking in previous quarter at 2588.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 87
Healthcare Sector # 259
Overall # 1922

Revenue TTM Y/Y Growth Statistics
High Average Low
-3.18 %
-3.18 %
-3.18 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 87
Sector # 259
S&P 500 # 1922




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
OCS's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue jump for the quarter ending Dec 31 2025 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2025
Theravance Biopharma inc 144.70%$ 144.700 millions
Voyager Therapeutics Inc 144.28%$ 144.282 millions
Esperion Therapeutics Inc 143.73%$ 143.725 millions
Foxo Technologies Inc 141.54%$ 141.542 millions
Volitionrx Limited133.25%$ 133.247 millions
Lineage Cell Therapeutics Inc 130.40%$ 130.404 millions
Tarsus Pharmaceuticals Inc 128.39%$ 128.388 millions
Evaxion A125.12%$ 125.120 millions
Cybin Inc 123.74%$ 123.742 millions
Elite Pharmaceuticals Inc 119.23%$ 119.225 millions
Pavmed Inc 116.67%$ 116.667 millions
Macrogenics Inc 113.03%$ 113.032 millions
C4 Therapeutics Inc 112.79%$ 112.787 millions
Vyne Therapeutics Inc 111.90%$ 111.905 millions
Tonix Pharmaceuticals Holding Corp 108.75%$ 108.753 millions
Phathom Pharmaceuticals Inc 94.12%$ 94.121 millions
Tenon Medical Inc 92.34%$ 92.338 millions
Caribou Biosciences Inc 89.74%$ 89.745 millions
Argenx Se89.08%$ 89.078 millions
Sangamo Therapeutics Inc 88.43%$ 88.425 millions
Agios Pharmaceuticals Inc 86.09%$ 86.086 millions
Oculis Holding Ag85.72%$ 85.722 millions
Alnylam Pharmaceuticals Inc 84.95%$ 84.945 millions
Day One Biopharmaceuticals Inc 83.92%$ 83.915 millions
Neuronetics Inc 82.17%$ 82.169 millions
Arcutis Biotherapeutics Inc 81.48%$ 81.478 millions
Aclarion Inc 80.59%$ 80.590 millions
X4 Pharmaceuticals Inc79.08%$ 79.079 millions
Intellia Therapeutics Inc 78.79%$ 78.787 millions
Envoy Medical Inc 78.57%$ 78.571 millions


About Oculis Holding Ag Revenue Growth Rates (OCS), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Oculis Holding Ag (CIK 1953530).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001193125-26-091446
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Oculis Holding Ag’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.